Programme Introduction Interview with Editor
Prof. University
Conference Spotlight
Industry Reflection Section
Programme Introduction Interview with Editor
Prof. University
Written topics preview, bullet points, infographics
Day 1
Tisagenlecleucel vs Standard of Care
Tisagenlecleucel vs standard of care as second-line therapy of primary refractory or relapsed agressive B-cell non-Hodgkin lymphoma
Interview with Prof. Michael Bishop,
University of Chicago, IL, USA
Day 2
Tisagenlecleucel vs Standard of Care
Tisagenlecleucel vs standard of care as second-line therapy of primary refractory or relapsed agressive B-cell non-Hodgkin lymphoma
Interview with Prof. Michael Bishop,
University of Chicago, IL, USA
Day 3
Tisagenlecleucel vs Standard of Care
Tisagenlecleucel vs standard of care as second-line therapy of primary refractory or relapsed agressive B-cell non-Hodgkin lymphoma
Interview with Prof. Michael Bishop,
University of Chicago, IL, USA
Day 4
Tisagenlecleucel vs Standard of Care
Tisagenlecleucel vs standard of care as second-line therapy of primary refractory or relapsed agressive B-cell non-Hodgkin lymphoma
Interview with Prof. Michael Bishop,
University of Chicago, IL, USA
Interview with Expert
Prof. University
Interview with Expert
Prof. University
Interview with Expert
Prof. University
This is a demo website for presentation purposes only!
The views and opinions of the interviewees and presenters are their own, and do not necessarily represent the stance or responsibility of the Editor nor the Publisher. The content is provided for informational purposes only and should not be considered official editorial content, endorsement or medical advice.
Copyright 2026: Medicom Education BV



